AUROPHARMA
11.02.2022 - CS on Auropharma Maintain Outperform CMP 684 Target 855
CREDIT SUISSE ON AUROBINDO : 14.07.2021
• Higher growth trajectory and improving RoCE to drive re-rating
• Increase FY22/23E EPS by 7%/8% and introduce FY24E
• High growth in FY24 reflects benefits of multiple growth drivers
* Generic injectables is now a large segment for Aurobindo
CS ON AUROBINDO PHARMA : 14.07.2021
* CS maintains Outperform call on Aurobindo Pharma with target being raised to rs 1,230/sh
* MAINTAIN OUTPERFORM TARGET: 1,230
• Increase FY22/23 EPS Estimates By 7%/8%
* High Growth In FY24 Reflects Benefits Of Multiple Growth Drivers
